Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Valganciclovir vs IV Ganciclovir for CMV Preemptive Treatment
NCT00241345Phase 3Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2004
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of valganciclovir in cytomegalovirus infection (CMV) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Clearance of CMV viremia as determined by quantitative CMV PCR assay at 4 weeks. Started Jun 2004; status: terminated.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00241345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00241345.